Ruxolitinib fails ... NEJM correspondence.
To the Editor: Zeiser et al. (July 15 issue)1 report a significantly better overall response in patients treated with ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease (GVHD), as they did 1 year ago for acute GVHD.2 The authors conclude that ruxolitinib was superior to control therapy, with no new safety signals. The data fail to convince. The authors describe chronic GVHD as “a leading cause…of nonrelapse-associated death.” However, overall survival did not differ substantially between the groups after half a year of treatment, with no fewer deaths from GVHD in the ruxolitinib group.
Cell Therapy News/Articles, page-11903
-
- There are more pages in this discussion • 6,107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |